The UC-Davis Medical Center which p...
The UC-Davis Medical Center which participated in Biopure Corporation's (Cambridge, MA) Phase 3 clinical trial of Hemopure [hemoglobin glutamer -- 250 bovine or HBOC-201] reported meditation results representing data from 35 of the 688 bring under rules treated in the trial. The multinational, randomized, r kindred cell-controlled, single-blind, parallel-group research assesses the study drug as an alternative to allogeneic r life-current cell transfusion in subjects undergoing elective orthopedic surgery Thus far, the rises have been positive. springs from SciClone Pharmaceuticals (San Mateo,
|